Qvanteq AG today announced that its QUEST I study was completed. The technology has shown safety in humans.
The topic of this 18 month program is the “Investigation of in vitro response of human blood to Qvanteq’s anti-thrombotic and pro-healing surface technology applied on vascular stents”.
Qvanteq AG today announced that it completed enrollment of QUEST I study patients.
Arik Zucker is one of the winners of the venture leader China program.